Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GK-001 in HCC prevention after curative treatment in chronic hepatitis C
2008-000566-23Phase 2Active
- Sponsor
- GeneCare Research Institute
- Start
- Mar 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing GK-001 with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Mar 2008; status: active.
02
Drugs
polaprezinc
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-000566-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000566-23.